Dr. Patnaik on a Study Examining SL-401 in Patients With Myeloproliferative Neoplasms

Mrinal S. Patnaik, MBBS
Published: Sunday, Dec 04, 2016

Mrinal S. Patnaik, MBBS, hematologist, Mayo Clinic, discusses a study investigating SL-401 in patients with myeloproliferative neoplasms during the American Society of Hematology (ASH) Annual Meeting.
SL-401 is a monoclonal antibody conjugate which targets a protein called CD-123, Patnaik explains. CD-123 is conjugated with a diphtheria toxin which increases its efficacy in killing malignant cells, Patnaik said.

The study was designed based on the success seen with CD-123 in a rate, but agressive, blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN).

<<< View more from the 2016 ASH Annual Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication